Notably, after TRIM63 depletion, the oncogenic effect of TRIM63 exhibited significant alterations exclusively in melanoma cells harboring BRAF mutations, while no such changes were observed in cells without BRAF mutation (Fig. 1J). This evidence concerns the gene BRAF and melanoma.